Food and Drug Administration officials are unhappy about the proliferation of ads for prescription drugs that minimize risk information, hype benefits, make unsupported claims and even fail to acknowledge serious product warnings.
Washington, D.C. - Food and Drug Administration officials are unhappy about the proliferation of ads for prescription drugs that minimize risk information, hype benefits, make unsupported claims and even fail to acknowledge serious product warnings. Tom Abrams , director of FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) says that the "quality of DTC advertising has declined" in recent years and that the overall tone of ads in less serious. Abrams called on marketers to make ads more educational and useful to consumers. Last year, DDMAC sent manufacturers 12 warning letters, compared with four to five in previous years, and Abrams expects this stepped-up compliance level to continue.
- Jill Wechsler
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
April 22nd 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More